MANSFIELD — Roche Bros Supermarkets Inc., a 20-store eastern Massachusetts grocery chain under the Roche Bros., Sudbury Farms and Brothers Marketplace banners, said it has entered into a ...

Here’s how it works. Ultra runner David Roche got back on the course this weekend to prove that his Leadville 100 win was no fluke. The runner snatched victory at The Javelina Jundred yesterday, just ...

After forming a gene therapy partnership with Dyno Therapeutics in 2020, Roche is back for more. In a new deal potentially worth more than $1 billion, Roche is paying Dyno $50 million upfront to ...

With an upfront payment of $50 million from Roche, the partnership will leverage Dyno Therapeutics’ in vivo gene therapy delivery technology, which synthesizes virus capsids with better functionality ...

Roche CEO: not good to limit competition in this space Roche says not itself, but others affected by Catalent deal Swiss drugmaker joins US peer Lilly in voicing opposition Eli Lilly and advocacy ...

Speaking to the press Wednesday, Roche’s chief executive Thomas Schinecker critiqued the proposed transaction, arguing that it could hamper the ability of smaller biopharma players to lock down ...

Roche doesn’t think so. “I think we don’t see anything that should be slowing Vabysmo momentum down,” Teresa Graham, CEO of Roche Pharmaceuticals, said during a press conference Wednesday ...

Roche ROG-0.57%decrease; red down pointing triangle confirmed its profit outlook for the year after its eye drug Vabysmo, multiple-sclerosis treatment Ocrevus and hemophilia injection Hemlibra ...

FRANKFURT, Oct 23 (Reuters) - The CEO of Roche (ROG.S), opens new tab said he has been informed that more cases of mpox infection have occurred in Europe than previously reported and that the ...

UCB will ad­vance its an­ti-tau an­ti­body for Alzheimer’s dis­ease so­lo af­ter Roche and Genen­tech walked away from the as­set known as bepranemab.

Roche has returned the rights to UCB’s anti-tau antibody bepranemab, walking away from a $120 million bet on the Alzheimer’s disease drug candidate on the cusp of the release of phase 2a data.

Roche drops a third Alzheimer’s candidate this year, terminating a partnership with UCB just four years after agreeing to work together on new treatments for the neurological disease. Roche has cut ...